Efficacy and safety of micafungin in the treatment of invasive fungal infections in patients with acute leukemia
10.3760/cma.j.issn.1000-6680.2011.03.013
- VernacularTitle:米卡芬净治疗急性白血病患者合并侵袭性真菌感染的疗效和安全性
- Author:
Jun MA
;
Yaochen ZHANG
;
Bing XU
;
Liping YE
;
Jiling JIANG
;
Xiaoqing LI
;
Wenrong HUANG
;
Ziling LIU
- Publication Type:Journal Article
- Keywords:
Mycoses;
Antifungal agents;
Peptides,cyclic;
Leukemia;
Acute disease
- From:
Chinese Journal of Infectious Diseases
2011;29(3):181-184
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the efficacy and safety of micafungin in the treatment of invasive fungal infections (IFI) in patients with acute leukemia.Methods A total of 133 IFI patients with acute leukemia received micafungin 150 mg once daily for 14 days.The clinical and mycological efficacies were evaluated on (7±2) days and(14±2) days of treatment.Meanwhile,the adverse events were recorded.The normally distributed data was compared using analysis of variance and nonnormal distributed data was analyzed using Wilcoxon rank-sum test.Results Among 133 IFI patients with acute leukemia,116 finished the 14-day micafungin treatment.The total clinical efficacy was 94.8% and the total mycological efficacy was 75.0% at (14±2) days of treatment.The fungus eliminate rates were 82.9%,66.7% and 55.6% against Monilia,Aspergillus and others,respectively.The clinical and mycological efficacies of (14±2)-day treatment were both higher than those of (7±2)-day treatment(X2=6.060,34.416.both P<0.05).The clinical efficacy was not related with age,sex,IFI diagnose,types of leukemia and combinative drugs (X2=26.541,P<0.05).The incidence of drug-related adverse events of micafungin was 3%among 133 patients,which included skin rash in 3 eases, diarrhea in 1 case. Only one case was discontinued because of severe skin rash and micafungin was well tolerant in other patients. Conclusion Treatment of micafungin 150 mg daily for 14 days is effective and safe in IFI patients with acute leukemia.
